Chikungunya: Valneva vaccine suspended in the United States after adverse effects
By SudOuest.fr with AFP
Valneva's Ixchiq vaccine suspended in the United States following the detection of new side effects
US health authorities have suspended approval of the anti-chikungunya vaccine developed by the Franco-Austrian laboratory Valneva, basing their decision on new cases of side effects , the group announced on Monday.
"This suspension is effective immediately and involves a halt to the shipment and sale of Ixchiq," the vaccine's brand name, "in the United States," Valneva detailed in a statement, while this treatment had been suspended in the spring for older people in the European Union before being reauthorized.
SudOuest
